Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2024-05-20 DOI:10.7573/dic.2024-1-2

S. Chiloiro, Marialuisa Appetecchia, Antonio Bianchi, Denise Costa, Christine De Acetis, Patrizia Gargiulo, A. Giampietro, Andrea M Isidori, M. Jaffrain-Rea, Marina Passeri, Francesca Pigliaru, Maurizio Poggi, L. De Marinis

引用次数: 0

查看原文本刊更多论文

复杂性肢端肥大症患者个性化治疗中的长期帕西洛肽-LAR治疗：临床经验集锦

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.